Business Description
Zoetis Inc
NAICS : 325412
SIC : 2834
10 Sylvan Way, Parsippany, NJ, USA, 07054
Compare
Compare
Traded in other countries / regions
ZOTS.Austria
•
Z1TS34.Brazil
•
ZOE.Germany
•
ZTS.Mexico
•
0M3Q.UK
•
ZTS.USA
Description
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.39 | |||||
| Equity-to-Asset | 0.33 | |||||
| Debt-to-Equity | 1.47 | |||||
| Debt-to-EBITDA | 2.08 | |||||
| Interest Coverage | 13.14 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 7.74 | |||||
| Beneish M-Score | -2.33 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 10.9 | |||||
| 3-Year EBITDA Growth Rate | 13.6 | |||||
| 3-Year EPS without NRI Growth Rate | 13.4 | |||||
| 3-Year FCF Growth Rate | 6.9 | |||||
| 3-Year Book Growth Rate | 28.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate Industry Rank | 10.76 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 9.49 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 48.1 | |||||
| 9-Day RSI | 47.88 | |||||
| 14-Day RSI | 49.23 | |||||
| 6-1 Month Momentum % | -11.74 | |||||
| 12-1 Month Momentum % | -13.37 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.18 | |||||
| Quick Ratio | 1.46 | |||||
| Cash Ratio | 0.87 | |||||
| Days Inventory | 302.49 | |||||
| Days Sales Outstanding | 54.49 | |||||
| Days Payable | 62.08 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.7 | |||||
| Dividend Payout Ratio | 0.26 | |||||
| 3-Year Dividend Growth Rate | 25.7 | |||||
| Forward Dividend Yield % | 0.74 | |||||
| 5-Year Yield-on-Cost % | 1.92 | |||||
| 3-Year Average Share Buyback Ratio | 0.5 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 70.23 | |||||
| Operating Margin % | 35.51 | |||||
| Net Margin % | 26.14 | |||||
| ROE % | 45.81 | |||||
| ROA % | 15.08 | |||||
| ROIC % | 24.7 | |||||
| ROC (Joel Greenblatt) % | 60.83 | |||||
| ROCE % | 24.01 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 39.56 | |||||
| Forward PE Ratio | 34.6 | |||||
| PE Ratio without NRI | 39.56 | |||||
| Shiller PE Ratio | 67.54 | |||||
| Price-to-Owner-Earnings | 55.77 | |||||
| PEG Ratio | 2.77 | |||||
| PS Ratio | 10.34 | |||||
| PB Ratio | 17.86 | |||||
| Price-to-Tangible-Book | 174.45 | |||||
| Price-to-Free-Cash-Flow | 58.01 | |||||
| Price-to-Operating-Cash-Flow | 41.89 | |||||
| EV-to-EBIT | 30.88 | |||||
| EV-to-Forward-EBIT | 29.97 | |||||
| EV-to-EBITDA | 26.48 | |||||
| EV-to-Forward-EBITDA | 25.44 | |||||
| EV-to-Revenue | 10.71 | |||||
| EV-to-Forward-Revenue | 10.38 | |||||
| EV-to-FCF | 60.41 | |||||
| Price-to-Projected-FCF | 3.59 | |||||
| Price-to-DCF (Earnings Based) | 1.04 | |||||
| Price-to-DCF (FCF Based) | 1.53 | |||||
| Price-to-Peter-Lynch-Fair-Value | 2.75 | |||||
| Price-to-Graham-Number | 17.48 | |||||
| Earnings Yield (Greenblatt) % | 3.22 | |||||
| Forward Rate of Return (Yacktman) % | 16.08 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NYSE:ZTS
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 7,995 | ||
| EPS (TTM) ($) | 4.41 | ||
| Beta | 0.76 | ||
| Volatility % | 27.42 | ||
| 14-Day RSI | 49.23 | ||
| 14-Day ATR ($) | 4.114277 | ||
| 20-Day SMA ($) | 176.7435 | ||
| 12-1 Month Momentum % | -13.37 | ||
| 52-Week Range ($) | 154.18 - 249.27 | ||
| Shares Outstanding (Mil) | 468.14 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Zoetis Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||